((自动化翻译由路透提供，请见免责声明 )) (在第 4 段中增加了股票走势，在第 2、3、5 段中增加了背景和详细信息)
路透10月18日 - 吉利德科学公司（Gilead Sciences ）周五表示，在与美国卫生监管机构协商后，该公司将自愿撤回其用于先前治疗过的一种膀胱癌患者的药物Trodelvy。
美国食品和药物管理局曾于 2021 年加速批准 Trodelvy（一种抗体药物共轭物）用于转移性尿路上皮癌的治疗，但是否继续批准取决于一项确证试验的结果。
然而，该药物在试验中未能改善晚期膀胱癌患者的生存率。
该制药商的股票在盘前交易中下跌了 1.3%，至 86.25 美元。
该公司表示，这一决定不会影响Trodelvy在美国境内或境外用于其他患者的审批。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.